Parkwood LLC’s Novartis NVS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $28.6M | Buy |
182,462
+19,098
| +12% | +$2.86M | 2.05% | 12 |
|
|
2026
Q1 | $25M | Buy |
163,364
+16,104
| +11% | +$2.47M | 2.21% | 7 |
|
|
2025
Q4 | $20.3M | Buy |
147,260
+14,294
| +11% | +$1.87M | 1.57% | 18 |
|
|
2025
Q3 | $17.1M | Sell |
132,966
-94,334
| -42% | -$11.5M | 1.55% | 17 |
|
|
2025
Q2 | $27.5M | Buy |
227,300
+120,923
| +114% | +$13.6M | 2.47% | 6 |
|
|
2025
Q1 | $11.9M | Sell |
106,377
-11,614
| -10% | -$1.24M | 1.09% | 38 |
|
|
2024
Q4 | $11.5M | Buy |
+117,991
| New | +$12.6M | 1.3% | 20 |
|
|
2020
Q4 | – | Sell |
-59,078
| Closed | -$5.14M | – | 122 |
|
|
2020
Q3 | $5.14M | Buy |
59,078
+1,506
| +3% | +$130K | 0.79% | 41 |
|
|
2020
Q2 | $5.03M | Sell |
57,572
-64,545
| -53% | -$5.57M | 0.9% | 35 |
|
|
2020
Q1 | $10.1M | Buy |
122,117
+49,818
| +69% | +$4.44M | 2.05% | 10 |
|
|
2019
Q4 | $6.85M | Buy |
72,299
+2,809
| +4% | +$252K | 1.44% | 23 |
|
|
2019
Q3 | $6.04M | Sell |
69,490
-64,909
| -48% | -$5.83M | 1.22% | 23 |
|
|
2019
Q2 | $12.3M | Buy |
134,399
+58,903
| +78% | +$4.99M | 2.62% | 8 |
|
|
2019
Q1 | $6.5M | Sell |
75,496
-86,210
| -53% | -$6.92M | 1.27% | 23 |
|
|
2018
Q4 | $12.4M | Buy |
161,706
+79,197
| +96% | +$6.16M | 2.85% | 7 |
|
|
2018
Q3 | $6.37M | Buy |
82,509
+768
| +0.9% | +$56.8K | 1.08% | 27 |
|
|
2018
Q2 | $5.53M | Sell |
81,741
-1,911
| -2% | -$132K | 0.87% | 32 |
|
|
2018
Q1 | $6.06M | Buy |
83,652
+18,213
| +28% | +$1.39M | 0.87% | 35 |
|
|
2017
Q4 | $4.92M | Buy |
65,439
+406
| +0.6% | +$30.6K | 0.67% | 40 |
|
|
2017
Q3 | $5M | Buy |
65,033
+6,649
| +11% | +$502K | 0.74% | 40 |
|
|
2017
Q2 | $4.37M | Buy |
58,384
+28,593
| +96% | +$2.03M | 0.65% | 41 |
|
|
2017
Q1 | $1.98M | Sell |
29,791
-9,683
| -25% | -$645K | 0.28% | 80 |
|
|
2016
Q4 | $2.58M | Buy |
39,474
+5,694
| +17% | +$369K | 0.4% | 64 |
|
|
2016
Q3 | $2.39M | Sell |
33,780
-3,273
| -9% | -$239K | 0.35% | 70 |
|
|
2016
Q2 | $2.74M | Buy |
37,053
+1,071
| +3% | +$74K | 0.46% | 60 |
|
|
2016
Q1 | $2.34M | Buy |
35,982
+29,966
| +498% | +$2.04M | 0.39% | 59 |
|
|
2015
Q4 | $464K | Buy |
6,016
+882
| +17% | +$70.1K | 0.07% | 271 |
|
|
2015
Q3 | $423K | Sell |
5,134
-70
| -1% | -$6.23K | 0.07% | 213 |
|
|
2015
Q2 | $459K | Buy |
5,204
+86
| +2% | +$7.89K | 0.06% | 209 |
|
|
2015
Q1 | $452K | Buy |
+5,118
| New | +$454K | 0.06% | 244 |
|
|
2014
Q4 | – | Sell |
-6,228
| Closed | -$525K | – | 509 |
|
|
2014
Q3 | $525K | Sell |
6,228
-4,474
| -42% | -$362K | 0.11% | 83 |
|
|
2014
Q2 | $868K | Buy |
+10,702
| New | +$842K | 0.2% | 66 |
|
Other funds holding NVS
Parkwood LLC's NVS Position: Q2 2026 in Review
Parkwood LLC increased its Novartis (NVS) stake by 12% in Q2 2026, buying an estimated $2.86M and bringing the position to 182,462 shares worth $28.6M. The position accounts for 2.05% of the portfolio, ranked #12.
Parkwood LLC first reported a position in NVS in Q2 2014 and has held it in 32 quarters since. 1,618 funds tracked by Wall St. Rank hold NVS as of Q2 2026.
- Parkwood LLC held 182,462 shares of Novartis worth $28.6M as of Q2 2026.
- Parkwood LLC bought 19,098 Novartis shares in Q2 2026, an estimated $2.86M.
- Novartis made up 2.05% of Parkwood LLC's portfolio in Q2 2026, its #12 holding.
- Parkwood LLC first reported a position in Novartis in Q2 2014 and has held it in 32 quarters since.
- 1,618 funds tracked by Wall St. Rank held Novartis as of Q2 2026.
Based on Parkwood LLC's 13F filing for Q2 2026, filed 14 Aug 2026.